证券代码：600833 证券简称：第一医药 公告编号：临2025-023 上海第一医药股份有限公司 第十届董事会第三十三次（临时）会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十届董事会第三十三次（临时）会议于2025年5月25 日以邮件方式通知，于2025年5月30日以通讯方式召开。本次会议由董事长张海波先生召集并主持。本 次会议应参加表决董事为9名，委托表决0名，实际参加表决董事9名。会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于取消监事会后〈公司章程〉及配套制度修订的议案》 具体内容详见同日刊载于上海证券交易所网站www.sse.com.cn《上海第一医药股份有限公司关于取消监 事会并修订〈公司章程〉及配套制度的公告》（公告编号：临2025-025）。 表决结果：赞成9名，反对0 ...

Investment Rating - The report assigns an "Overweight" (OW) rating to Mindray, Genscript, and Dashenlin, indicating a positive outlook for these companies in the healthcare sector [9][21]. Core Insights - The domestic market recovery for Mindray is on track despite macro challenges, with overseas sales expected to grow by approximately 15% in FY25. The company anticipates meaningful growth in the second half of 2025 due to increased hospital tender activities and a government funding injection of around Rmb 20 billion for medical equipment replacement [2]. - Snibe expects a recovery in its IVD business starting in the second half of 2025, with guidance for single-digit growth in China sales for FY25 and double-digit growth anticipated in 4Q25 and the following year [3]. - Genscript's ProBio business is projected to drive future growth, with no changes in guidance despite geopolitical developments. The company expects to reach breakeven once sales hit US$150 million to US$160 million [4][8]. - Dashenlin is positioned as a top pick in the pharmacy space, forecasting a 25% profit growth and around 10% revenue growth for FY25, alongside a significant store expansion plan [9]. Summary by Company Mindray - Domestic market recovery is progressing, with overseas sales growth projected at 15% for FY25. Management expects significant growth in the second half of 2025 due to increased hospital tender activities and a Rmb 20 billion funding injection from the government [2]. Snibe - The company anticipates a recovery in its IVD business in 2H25, with a projected single-digit growth in China sales for FY25. The overall China IVD market size is expected to shrink by approximately 10% in 2025 but recover to over 5% growth in the long term [3]. Genscript - The ProBio business is expected to drive future growth, with management maintaining guidance despite geopolitical challenges. The company anticipates breakeven at US$150 million to US$160 million in sales [4][8]. Dashenlin - The company is expected to achieve a 25% profit growth and around 10% revenue growth for FY25, with a net increase of approximately 2,300 stores planned. Industry consolidation is expected to accelerate, benefiting leading chains like Dashenlin [9].

证券代码：600713 证券简称：南京医药 编号：ls2025-075 债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据发行文件中相关条款规定，南京医药股份有限公司 2023 年度第一期中期 票据（债券简称：23 南京医药 MTN001，债券代码：102381470）设有投资人回售 选择权，经前期回售登记，现将本次行权结果公告如下： 一、本期债券基本情况 发行人名称 南京医药股份有限公司 债券名称 南京医药股份有限公司 2023 年度第一期中期票据 债券简称 23 南京医药 MTN001 债券代码 102381470 发行金额（万元） 100,000 起息日 2023-06-20 发行期限 2+1 年 债项余额（万元） 100,000 本计息期债项利率（%） 3.1 主承销商 交通银行股份有限公司、兴业银行股份有限公司 存续期管理机构 交通银行股份有限公司 登记托管机构 银行间市场清算所股份有限公司 二、本次行权结果情况 投资人回售申请开始日 2025- ...

Core Insights - The event marked the recognition of China Resources Pharmaceutical Group as a member of the China Anti-Cancer Association, highlighting the collaboration between the two entities in cancer prevention and treatment [2][4][6] Group 1: Event Overview - The event was themed "Empowerment through Integration" and included a visit to the innovation center of China Resources Pharmaceutical Group, showcasing its patient-centered innovations over 75 years [4][5] - Key figures from the China Anti-Cancer Association, including its president and vice presidents, attended the event, emphasizing the importance of collaboration in cancer treatment [2][6] Group 2: Strategic Initiatives - The China Anti-Cancer Association introduced 17 strategic measures under the guidance of integrated medicine, aiming to enhance cancer prevention and treatment in China [5][6] - The association's "China Cancer Integrated Diagnosis and Treatment Guidelines" established a comprehensive system for cancer care, including over 70 technical guidelines and 60 cancer type guidelines [5][6] Group 3: Industry Collaboration - China Resources Pharmaceutical Group aims to integrate resources across research, education, and application to improve patient access to innovative drugs, positioning itself as a leader in the pharmaceutical distribution sector [6][9] - The company plans to enhance collaboration with the China Anti-Cancer Association to build a new ecosystem for cancer prevention and treatment, supporting the Healthy China strategy [6][9] Group 4: Challenges and Opportunities - The Chinese pharmaceutical industry is entering a new phase driven by product innovation, but faces challenges such as shortened product life cycles and commercialization difficulties [6][9] - The company is leveraging its extensive distribution network and experience to improve patient accessibility and address the challenges in drug availability and payment [6][9]

医药商业板块短线走低，第一医药（600833）跌超6%，一心堂（002727）、浙江震元（000705）、漱 玉平民（301017）、润达医疗（603108）等跟跌。 这几只票暗盘资金正在偷偷流入，立即查看>> ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - As of May 27, HeFu China's closing price was 6.78 yuan, with a PE ratio of 187.01, significantly higher than the industry average of 42.04 and median of 28.02 [1][2] - The total market capitalization of HeFu China is reported at 2.699 billion yuan [1][2] Group 2 - HeFu China's main business involves international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - The latest quarterly report for Q1 2025 shows HeFu China achieved a revenue of 176 million yuan, representing a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, a decline of 184.13% [1] - The gross profit margin for the company stands at 16.71% [1] Group 3 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Group 1 - The core viewpoint is that the pharmaceutical sector is gradually recovering, reflected in the performance of listed companies, despite limited overall index growth [1] - The manager emphasizes a balanced approach to investment, focusing on risk-reward ratios and aiming for excess returns relative to the pharmaceutical index over time [1] - The fund manager has a strong track record, with the fund achieving a return of 87.60% since inception, ranking first in its category for various time frames [1] Group 2 - The fund's investment scope includes various segments of the pharmaceutical and healthcare industry, such as chemical pharmaceuticals, traditional Chinese medicine, biological products, and medical services [2] - The top ten holdings of the fund are diversified across high-growth areas like innovative drugs and medical devices, which helps mitigate individual stock volatility while participating in overall industry growth [2] - The holdings are balanced, reducing the risk associated with any single stock and enhancing exposure to the sector's growth potential [2]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-022 上海第一医药股份有限公司 关于参与设立基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、基金情况概述 上海第一医药股份有限公司（以下简称 "公司"）参与投资设立上海创特私募投 资基金合伙企业（有限合伙）（以下简称"基金"），具体详见公司于 2025 年 4 月 9 日披露的《上海第一医药股份有限公司关于参与设立基金暨关联交易的公告》（公告 编号：临 2025-016）。 此前，基金已完成工商注册登记，并完成基金首期实缴 1000 万元，具体详见公司 于 2025 年 4 月 26 日披露的《上海第一医药股份有限公司关于参与设立基金的进展公 告》（公告编号：临 2025-017）。 公司于 2025 年 5 月 15 日披露的《上海第一医药股份有限公司关于参与设立基金备案 完成的公告》（公告编号：临 2025-021）。 二、基金进展情况 截至目前，基金整体实缴已全部完成，基金各合伙人实缴出资情况如下： 实缴出资总 序号 出资人名称 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 根据《公司法》《上市公司股份回购规则》等相关规定，一心堂药业集团股份有限公司（以下简称"公 司"或"本公司"）通过股份回购专用证券账户持有的本公司股份11,475,900股不享有参与权益分派的权 利。本次权益分派以2024年度权益分派方案实施时股权登记日的总股本585,604,125股扣除公司股份回购 专用证券账户股份数11,475,900股后的574,128,225股为基数，向全体股东每10股派发现金红利3元(含 税)，不送红股，不以资本公积金转增股本，本次预计现金分红总额为172,238,467.50元（含税)。 公司2024年年度权益分派方案已获2025年5月21日召开的2024年年度股东会审议通过，现将权益分派事 宜公告如下： 一、股东会审议通过的权益分派方案情况 1、公司2024年年度股东会审议通过的利润分配方案为：公司决定以2024年度权益分派方案实施时股权 登记日的总股本扣除公司回购专用账户股份数（截至公告披露日，公司股份回购专用证券账户 ...

医药生物 | 证券研究报告 — 调整盈利预测 2025 年 5 月 26 日 605266.SH 买入 原评级：买入 市场价格:人民币 23.01 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 4.8 14.5 6.9 (55.9) 相对上证综指 2.2 12.9 7.8 (63.4) 发行股数 (百万) 154.54 (57%) (44%) (30%) (16%) (2%) 12% May-24 Jun-24 Jul-24 Aug-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 健之佳 上证综指 | 流通股 (百万) | 154.54 | | --- | --- | | 总市值 (人民币 百万) | 3,556.03 | | 3 个月日均交易额 (人民币 百万) | 68.33 | | 主要股东持股比例（%） | | | 深圳市畅思行实业发展有限公司 | 15.17 | 资料来源：公司公告， Wind ，中银证券 以 2025 年 5 月 23 日收市价为标准 中银国际证券股份有限公司 具备证券投 ...